ArticleJournal of human genetics2026
HOXB13, a high-risk prostate cancer gene, also confers risk for breast cancer: novel variants of clinical significance, especially in hormone-positive patients.
Article in Journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Germline mutations in high-risk genes, such as BRCA1 and BRCA2, are primarily responsible for inherited breast cancers, while mutations in moderate-risk genes also increase susceptibility. HOXB13 is established as a high-risk gene for prostate cancer (PCa), but few studies have explored its role in breast cancer. Here, we report, for the first time, novel HOXB13 variants identified in breast cancer patients, suggesting a potential association that warrants further investigation. This retrospective cohort study was conducted at the Medical Genetics Laboratory of Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Turkey, between 2022 and 2025. A total of 4198 individuals who underwent hereditary cancer panel testing were screened. Targeted next-generation sequencing was performed using a Custom Hereditary Cancer (cHCS) panel on the Illumina NextSeq® platform. Raw sequencing data were analyzed using Dragen v3.6 and Sophia DDM pipelines. Among 4198 individuals, 1527 had a confirmed breast cancer diagnosis. Eleven patients harbored variants of uncertain significance (VUS) in HOXB13. Hormone-negative patients (n = 3) carried c.269del, c.766 T > C, and c.309_311del variants. Among hormone-positive patients (n = 8), two carried c.309_311del, one had c.404 G > A, and five carried c.728 A > G (p.K243R), the most frequent variant in this subgroup. The HOXB13 variant spectrum in the Turkish population differed from previously reported data. Novel HOXB13 variants, particularly c.728 A > G (p.K243R), may represent candidate variants of interest that require further validation before any clinical application. These findings highlight a potential association between HOXB13 variants and breast cancer, particularly in hormone receptor-positive patients, and emphasize the need for larger and functionally validated studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.